Hastina 24+4 (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

Hastina 24+4 is prescribed as a combined hormonal contraceptive for several gynecological indications.

• Prevention of pregnancy by consistently inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining.
• Regulation of menstrual cycles, helping to achieve more predictable bleeding patterns and reduce irregular spotting.
• Reduction of moderate acne that can be linked to hormonal fluctuations, offering an additional dermatologic benefit.
• Relief of dysmenorrhea and menstrual‑related pelvic pain, often resulting in improved daily comfort during periods.
• Management of premenstrual syndrome symptoms such as mood swings, breast tenderness, and bloating, supporting overall well‑being.

Like other combined oral contraceptives, Hastina 24+4 may be associated with a range of side effects that vary in frequency and severity.

Common

• Nausea, occasional vomiting, or mild stomach upset, especially when first starting the tablet.
• Headache, including tension‑type or mild migraine, which often improves after several cycles.
• Breast tenderness, swelling, or a feeling of fullness that may lessen over time.
• Spotting, breakthrough bleeding, or irregular bleeding between scheduled periods, typically decreasing after the first few months.

Serious

• Deep vein thrombosis, pulmonary embolism, or other thromboembolic events, which require immediate medical attention.
• Severe hypertension, stroke, myocardial infarction, or other serious cardiovascular complications.

Before prescribing Hastina 24+4, clinicians evaluate several safety considerations to minimize risk and ensure appropriate use.

• Contraindicated in women who are pregnant, breastfeeding, or have a known hypersensitivity to any component.
• Not recommended for individuals with a history of thromboembolic disorders, stroke, or myocardial infarction.
• Caution in smokers aged 35 years or older due to increased cardiovascular risk.
• Use with caution in patients with uncontrolled hypertension, diabetes mellitus, or liver disease.
• May affect lipid metabolism; periodic monitoring of cholesterol levels is advisable.
• Consider potential interaction with hormonal conditions such as estrogen‑dependent tumors.

Hastina 24+4 can interact with other medicines, which may alter its effectiveness or increase adverse effects.

Avoid

• Concomitant use with potent enzyme inducers such as rifampin, carbamazepine, or phenytoin, which can reduce contraceptive efficacy.
• Combined use with other hormonal contraceptives, which may increase the risk of hormonal side effects.

Use with caution

• Antifungal agents like ketoconazole or itraconazole that inhibit CYP3A4, potentially raising hormone levels.
• Certain antibiotics (e.g., clarithromycin) that may modestly affect hormone metabolism.
• Herbal supplements containing St. John’s Wort, which can decrease plasma concentrations of the active hormones.
• Medications that affect fluid balance, such as diuretics, may require blood pressure monitoring.